A potent combination in all cell lines tested was MCL-1 with BCL-xL inhibition, with over 80% cell death observed in K562 (89.44 ± 3.15%), BV173 (88.89 ± 2.91%), and CML-T1 (86.49 ± 5.65%) cells, and over 45% cell death in KCL-22 cells; significantly more than either treatment alone (Fig. 3A, Supplementary Table 4). Here, BCL2L1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.